RMC-6236 is under clinical development by Revolution Medicines and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RMC-6236’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RMC-6236 overview
RMC-6236 is under development for the treatment of solid tumor, colorectal cancer, pancreatic ductal adenocarcinoma cancer, melanoma, gynecological cancer and non-small cell lung cancer. It is administered through oral route. The drug candidate is a RAS-selective, tri-complex inhibitor. It acts by targeting the GTP bound form of KRAS (G12V, G12D, G13C, G13D, Q61H), NRAS (Q61X) and HRAS mutants.
Revolution Medicines overview
Revolution Medicines is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. The company’s pipeline products include RMC-6236 an investigational, oral, RAS(ON) multi-selective non-covalent inhibitor designed to treat pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and other solid tumors; and RMC-6291 and is an investigational, oral, RAS (ON) G12C and G12D selective covalent inhibitors that target solid tumors and non-small cell lung cancer. Its preclinical RAS(ON) mutant-selective inhibitors and RAS companion inhibitors comprise RMC-5127, RMC-0708, RMC-8839, RMC-4630 and RMC-5552. The company operates through its subsidiaries in the US and the UK. Revolution Medicines is headquartered in Redwood City, California, the US.
For a complete picture of RMC-6236’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
